window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : September 15, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

PharmaForceIQ

  • Biotech & Pharma Business,Digital & Data

    PharmaForceIQ launches AI platform for pharma commercial teams

    PharmaForceIQ has launched Optichannel 360, an AI platform that connects [...]

    August 28, 2026
  • Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics

    PharmaForceIQ acquires Aktana to expand AI-driven pharma engagement platform

    PharmaForceIQ has acquired Aktana, bringing together a digital commercial orchestration [...]

    May 5, 2026
  • Digital & Data,Drug Discovery & Development

    PharmaForceIQ reports strong growth as demand for optichannel strategies rises

    PharmaForceIQ, an independent provider of precision customer engagement technologies for [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • FDA approves Protagonist’s Mimrylo for polycythemia vera, triggering $275M in payments
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics
  • Isomab data support safety of angiogenic approaches in coronary artery disease
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • FDA approves Tivicay PD for children with HIV weighing at least 2kg
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top